Two pathogen reduction technologies–methylene blue plus light and shortwave ultraviolet light–effectively inactivate hepatitis C virus in blood products (2012)

Peer-Reviewed Study · Steinmann E, Gravemann U, Friesland M, et al. · August 21, 2012

Steinmann E et al., 2012-08-21: Cell-culture study using infectious HCV showing that the Theraflex MB-Plasma system inactivates HCV in plasma below the detection limit at one-twelfth of the full light dose. In-vitro blood-product work, not patient treatment.

HCV in plasma was efficiently inactivated by MB plus light below the detection limit already by 1/12 of the full light dose.

Steinmann E et al., 2012-08-21: Cell-culture study using infectious HCV showing that the Theraflex MB-Plasma system inactivates HCV in plasma below the detection limit at one-twelfth of the full light dose. In-vitro blood-product work, not patient treatment. Study type: in vitro blood-product spiking with cell-culture-derived HCV and BVDV. N/A. Country: Germany (Twincore, Hannover, with DRK Springe). MB plus visible light, Theraflex MB-Plasma system (MacoPharma); full light dose and 1/12 dose tested; MB concentration not in abstract. Funding: not stated in record. Conflicts: none stated; MacoPharma supplied the systems (named as manufacturer). Comparator: UVC Theraflex UV-Platelets and untreated units. Study type: lab.